Journal article
Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity
Abstract
BACKGROUND: Bleeding is a complication of treatment with factor Xa inhibitors, but there are no specific agents for the reversal of the effects of these drugs. Andexanet is designed to reverse the anticoagulant effects of factor Xa inhibitors.
METHODS: Healthy older volunteers were given 5 mg of apixaban twice daily or 20 mg of rivaroxaban daily. For each factor Xa inhibitor, a two-part randomized placebo-controlled study was conducted to …
Authors
Siegal DM; Curnutte JT; Connolly SJ; Lu G; Conley PB; Wiens BL; Mathur VS; Castillo J; Bronson MD; Leeds JM
Journal
New England Journal of Medicine, Vol. 373, No. 25, pp. 2413–2424
Publisher
Massachusetts Medical Society
Publication Date
December 17, 2015
DOI
10.1056/nejmoa1510991
ISSN
0028-4793